Inovio Pharmaceuticals Inc (INO): Inovio CEO Interview: PD1/PDL1 Inhibitors, Immunotherapy And Why Investors Should Be Excited About 2014 - Seeking Alpha
This is an outstanding article on Inovio, a biotech company that is involved in developing anti-cancer and anti-infection drugs. The company really turned the corner this year with its partnership with Roche, a large drug company. This provided financial stability and trust in Inovio.
As a person who has been burned by biotech stocks in the past, INO is one of the few drug stocks that I currently own. My good and bad experiences in the biotech field help me to see the real winners when they appear on the scene. I believe Inovio will become a multi-bagger stock in the coming years.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment